Related Experiment Video
Updated: Aug 12, 2026
10:40
Measuring Neuromuscular Junction Functionality
Published on: August 6, 2017
Deficiency of sympathetic nervous system function in myasthenia
1Institute of Neurology and Psychiatry, Bucharest, Romania.
Journal of the Autonomic Nervous System
|April 1, 1992
Summary
Myasthenic patients exhibit sympathetic deficiency, showing reduced norepinephrine responses and increased epinephrine release during stress tests. This suggests a compensatory mechanism for their noradrenergic deficit.
Area of Science:
- Neuroscience
- Endocrinology
- Clinical Medicine
Background:
- Myasthenia gravis is an autoimmune disorder affecting neuromuscular junctions.
- Autonomic nervous system dysfunction can occur in myasthenia gravis.
- Norepinephrine and epinephrine are key catecholamines involved in stress responses.
Purpose of the Study:
- To investigate the norepinephrine (NE) and epinephrine (E) responses to physiological stressors in myasthenic patients.
- To compare autonomic responses in myasthenia gravis with a control group (lumbar disc disease).
- To explore the implications of altered catecholamine excretion for sympathetic function in myasthenia gravis.
Main Methods:
- Urinary excretion of NE and E was measured in myasthenic patients and controls.
- Stimuli included forearm ischemia, orthostasis, and exercise.
- Comparison of catecholamine responses between patient and control groups.
Main Results:
- Control subjects showed increased NE excretion with stimuli, while E excretion remained stable.
- Myasthenic patients displayed increased E excretion and unchanged or decreased NE excretion.
- This pattern was consistent across forearm ischemia, orthostasis, and exercise challenges.
Conclusions:
- Myasthenic patients exhibit a blunted NE response, indicative of sympathetic deficiency.
- Elevated E excretion in myasthenia gravis appears to be a compensatory reaction to sympathetic deficit.
- The noradrenergic deficit in myasthenia gravis may be linked to underlying cholinergic hyperactivity.
Related Concept Videos
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:15Myasthenia Gravis: Diagnostic Tests
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
01:28Disorders of the Skeletal Muscle
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
01:26Chemical Synapses
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...